ICU Medical (ICUI) is back in focus after third quarter results topped earnings and revenue expectations, driven by record Infusion Systems and Consumables sales and firmer adjusted profitability, with management reaffirming full year guidance near the upper end. Recent price action has picked up, with a 1-day share price return of 2.66%, a 7-day gain of 5.09%, and a 30-day rise of 10.31% taking ICU Medical to US$172.11. At the same time, a year-to-date share price return of 24.24% and a...
ICU Medical reported third quarter 2026 sales of US$560.44 million and net income of US$26.85 million, with basic earnings per share from continuing operations of US$1.07. Adjusted earnings and revenue exceeded analyst expectations, and the company reaffirmed its full year guidance. Stronger adjusted profitability, improved gross margin performance and debt reduction using robust free cash flow suggest ICU Medical is tightening its cost base while still funding product development and...
ICU Medical Inc (ICUI) posted 5% organic revenue growth with record Infusion Systems and Consumables sales, while logistics consolidation weighed on Vital Care and tariff costs remained a headwind.
Detailed price information for Flowserve Corp (FLS-N) from The Globe and Mail including charting and trades.
Detailed price information for I C U Medical Inc (ICUI-Q) from The Globe and Mail including charting and trades.
The sale was part of a trading plan established in June.
Bonnell retains 62,443 direct shares.
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Drug Reconstitution Systems Market - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global drug reconstitution systems market is projected to increase from approximately USD 5.9 billion in 2026 to USD 10.8 billion by 2035, representing a compound annual growth rate (CAGR) of about 7.0% during the forecast period. Market expansion is being supported by the growing pipeline of biologics, biosimilars, vaccines,
Brian Michael Bonnell, Chief Financial Officer, on August 31, 2026, sold 9,307 shares in ICU Medical
SAN CLEMENTE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference on September 9-10, 2026 Company management will attend the Wells Fargo 21st Annual Healthcare Conference, held at the Encore Boston Harbor in Boston, MA, participating in one-on-one meetings on Wednesday, Sept
The Otsuka ICU Medical joint venture, formed last year by ICU Medical and Otsuka Pharmaceutical Factory, is nearly doubling its Austin manufacturing campus in its first major expansion.
Let’s dig into the relative performance of ICU Medical (NASDAQ:ICUI) and its peers as we unravel the now-completed Q2 medical devices & supplies - cardiology, neurology, vascular earnings season.
This is the newest page. Registered accounts read further back.